HUE067036T2 - 2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében - Google Patents

2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében

Info

Publication number
HUE067036T2
HUE067036T2 HUE17871457A HUE17871457A HUE067036T2 HU E067036 T2 HUE067036 T2 HU E067036T2 HU E17871457 A HUE17871457 A HU E17871457A HU E17871457 A HUE17871457 A HU E17871457A HU E067036 T2 HUE067036 T2 HU E067036T2
Authority
HU
Hungary
Prior art keywords
hydroxybenzylamine
prevention
treatment
pulmonary hypertension
hypertension
Prior art date
Application number
HUE17871457A
Other languages
English (en)
Hungarian (hu)
Inventor
Joshua Fessel
L Roberts
James West
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of HUE067036T2 publication Critical patent/HUE067036T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE17871457A 2016-11-15 2017-11-15 2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében HUE067036T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662422486P 2016-11-15 2016-11-15

Publications (1)

Publication Number Publication Date
HUE067036T2 true HUE067036T2 (hu) 2024-09-28

Family

ID=62145792

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17871457A HUE067036T2 (hu) 2016-11-15 2017-11-15 2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében

Country Status (9)

Country Link
US (2) US20190314302A1 (enExample)
EP (2) EP3541185B1 (enExample)
JP (1) JP7383285B2 (enExample)
CN (1) CN110177463B (enExample)
AU (1) AU2017362328B2 (enExample)
ES (1) ES2981715T3 (enExample)
HU (1) HUE067036T2 (enExample)
PL (1) PL3541185T3 (enExample)
WO (1) WO2018093936A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
US20220162240A1 (en) 2019-01-25 2022-05-26 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers
EP4097115A4 (en) * 2020-01-27 2024-03-13 Vanderbilt University ANTI-MITOCHONDRIAL ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF
JP2023545304A (ja) * 2020-10-13 2023-10-27 ヴァンダービルト ユニバーシティー 腎傷害による腸リンパ管の乱れを予防する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521349A (ja) 2003-03-27 2006-09-21 メディキュア インコーポレーテッド 狭心症を治療するための組成物
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
JP5132109B2 (ja) 2006-09-01 2013-01-30 花王株式会社 一剤式染毛剤組成物
EP3597188A1 (en) * 2006-11-13 2020-01-22 PCB Associates, Inc. An isolated phycobilin for use in a method for prophylaxis or treatment of a medical condition
US8314015B2 (en) 2010-07-14 2012-11-20 Sharp Laboratories Of America, Inc. Silicon surface modification for the electrochemical synthesis of silicon particles in suspension
MX383365B (es) * 2011-07-12 2025-03-13 Univ Vanderbilt Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
US20150031068A1 (en) * 2012-03-19 2015-01-29 Lycera Corporation Methods and compositions for detecting immune system activation
WO2015127163A1 (en) * 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Also Published As

Publication number Publication date
EP3541185A4 (en) 2020-06-24
EP3541185B1 (en) 2024-04-24
EP4385576A2 (en) 2024-06-19
PL3541185T3 (pl) 2024-08-12
WO2018093936A1 (en) 2018-05-24
CN110177463B (zh) 2022-03-08
EP3541185A1 (en) 2019-09-25
AU2017362328B2 (en) 2022-03-31
CN110177463A (zh) 2019-08-27
JP7383285B2 (ja) 2023-11-20
US20190314302A1 (en) 2019-10-17
ES2981715T3 (es) 2024-10-10
EP3541185C0 (en) 2024-04-24
AU2017362328A1 (en) 2019-06-27
JP2019536778A (ja) 2019-12-19
US20250381155A1 (en) 2025-12-18
EP4385576A3 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
IL259751B (en) Polycyclic compounds and their use in the treatment of immune disorders
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL261932A (en) Use of probiotics in the treatment and/or prevention of eczema
SI4014976T1 (sl) Aprocitentan za uporabo pri zdravljenju hipertenzije in sorodnih bolezni v kombinaciji z valsartanom
HRP20180260T1 (hr) Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja
ZA201901055B (en) Treatment and prevention of sleep disorders
PL3484585T5 (pl) Zastosowanie probiotyków w leczeniu i/lub zapobieganiu atopowemu zapaleniu skóry
ZA201704726B (en) Peptides and their use in the treatment of skin
IL266128B (en) History of naphthyridinone and its use in the treatment of arrhythmia
PL3541185T3 (pl) Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu
ZA201905402B (en) Compounds and their use in the treatment of schistosomiasis
HUE058749T2 (hu) Készítmények és módszerek homocisztinuria kezelésében történõ alkalmazásra
HUE050456T2 (hu) Dimetil-amino-mikeliolid tüdõfibrózis kezelésében történõ alkalmazásra
PL3197556T3 (pl) KOMPOZYCJA DO ZAPOBIEGANIA l/LUB LECZENIA OBJAWÓW ALERGII
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
GB2546965B (en) Improvements in and relating to the treatment of arthrofibrosis
PT3408287T (pt) Gdf15 em glaucoma e respetivos métodos de utilização
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu
IL265242B (en) Compounds for the treatment of hypertension and/or fibrosis
SG11201802955VA (en) Peptides of use in the preventive and curative treatment of alopecia
TH1801002163A (th) เพปไทด์เพื่อใช้ในการรักษาป้องกันและเยียวยาภาวะศีรษะล้าน
PL3152193T3 (pl) Pochodne tetrahydroizochinolinonu i ich zastosowanie do hamowania białka hsp70
PL3280430T3 (pl) Peptyd QBP1 do stosowania w zapobieganiu lub leczeniu zespołu stresu pourazowego, ostrego zaburzenia stresowego oraz ogólnego zespołu adaptacyjnego
GB201403086D0 (en) Selection of virus and agent useful in the treatment of cancer